期刊： CELL REPORTS MEDICINE, 2022; 3 (7)
This is a phase Ib study of anlotinib plus a programmed death-ligand 1 (PD-L1) inhibitor TQB2450 for plat-inum-resistant or-refractory ovarian cancer.......
期刊： CELL REPORTS MEDICINE, 2022; 3 (12)
Direct in vivo investigation of human placenta trophoblast's susceptibility to SARS-CoV-2 is challenging. Here we report that human trophoblast stem c......
期刊： CELL REPORTS MEDICINE, 2022; 3 (7)
Treating and preventing chronic pain require our understanding of how it develops and maintains. Loffler et al. (2022)(1) demonstrate that distinct op......
期刊： CELL REPORTS MEDICINE, 2022; 3 (10)
Increasing evidence indicates that gut microbiota may play a key role in vaccination immunity. Here, we investigate whether the human gut microbiota a......
期刊： CELL REPORTS MEDICINE, 2022; 3 (3)
Prostate cancer continuously progresses following deprivation of circulating androgens originating from the testis and adrenal glands, indicating the ......
期刊： CELL REPORTS MEDICINE, 2022; 3 (7)
Triple-negative breast cancer (TNBC) is a subset of breast cancer with an adverse prognosis and significant tumor heterogeneity. Here, we extract quan......
期刊： CELL REPORTS MEDICINE, 2022; 3 (9)
Although the MAPK pathway is aberrantly activated in triple-negative breast cancers (TNBCs), the clinical outcome of MEK-targeted therapy is still poo......
期刊： CELL REPORTS MEDICINE, 2022; 3 (10)
Overconsumption of carbohydrate-rich food combined with adverse eating patterns contributes to the increasing incidence of metabolic syndrome (MetS) i......
期刊： CELL REPORTS MEDICINE, 2022; 3 (3)
Recently, a novel dog-origin coronavirus has been found in humans. The low similarity between the receptor-binding domain from this novel virus and ot......
期刊： CELL REPORTS MEDICINE, 2022; 3 (6)
Glucocorticoid-induced tumor necrosis factor receptor (GITR) is a co-stimulatory receptor and an important target for cancer immunotherapy. We herein ......
期刊： CELL REPORTS MEDICINE, 2022; 3 (4)
Rui-Hua Xu completed the REGOTORI trial that showed a novel combination regimen, regorafenib plus toripalimab, improved the efficacy and survival of r......
期刊： CELL REPORTS MEDICINE, 2022; 3 (10)
Pan-coronavirus'' antivirals targeting conserved viral components can be designed. Here, we show that the rationally engineered H84T-banana lectin (H8......
期刊： CELL REPORTS MEDICINE, 2022; 3 (12)
Tumor-infiltrating lymphocytes (TILs), especially CD8+ TILs, represent a favorable prognostic factor in high-grade serous ovarian cancer (HGSOC) and o......
